These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 20038864

  • 1. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia.
    Lalloum F, Souied EH, Bastuji-Garin S, Puche N, Querques G, Glacet-Bernard A, Coscas G, Soubrane G, Leveziel N.
    Retina; 2010 Mar; 30(3):399-406. PubMed ID: 20038864
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.
    Lai TY, Chan WM, Liu DT, Lam DS.
    Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555
    [Abstract] [Full Text] [Related]

  • 4. Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab.
    Varano M, Tedeschi M, Oddone F, Perillo L, Coppè AM, Parravano M.
    Retina; 2010 Mar; 30(3):413-7. PubMed ID: 20010453
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
    Rouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas I, Markomichelakis N.
    Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
    [Abstract] [Full Text] [Related]

  • 7. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
    Chan WM, Lai TY, Liu DT, Lam DS.
    Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
    [Abstract] [Full Text] [Related]

  • 8. Intravitreal ranibizumab treatment of macular choroidal neovascularization secondary to angioid streaks: one-year results of a prospective study.
    Ladas ID, Kotsolis AI, Ladas DS, Niskopoulou M, Georgalas I, Papakonstantinou D, Rouvas AA.
    Retina; 2010 Sep; 30(8):1185-9. PubMed ID: 20539257
    [Abstract] [Full Text] [Related]

  • 9. Intravitreal ranibizumab for choroidal neovascularization in angioid streaks.
    Mimoun G, Tilleul J, Leys A, Coscas G, Soubrane G, Souied EH.
    Am J Ophthalmol; 2010 Nov; 150(5):692-700.e1. PubMed ID: 20719301
    [Abstract] [Full Text] [Related]

  • 10. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
    Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Bandello F.
    Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Multifocal electroretinography and optical coherence tomography changes after repeated intravitreal bevacizumab (Avastin) in myopic choroidal neovascularization.
    Sabry D, Gad MA, Enam KM.
    Retina; 2013 Mar; 33(3):598-605. PubMed ID: 23064427
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.
    Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Cascavilla ML, Bandello F.
    Retina; 2012 Sep; 32(8):1539-46. PubMed ID: 22922846
    [Abstract] [Full Text] [Related]

  • 15. Macular functional changes evaluated with MP-1 microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal neovascularization: one-year results.
    Scupola A, Tiberti AC, Sasso P, Savastano MC, Mastrocola A, Marangoni D, Minnella AM, Falsini B, Balestrazzi E.
    Retina; 2010 May; 30(5):739-47. PubMed ID: 20038860
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.
    Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB.
    Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547
    [Abstract] [Full Text] [Related]

  • 18. [Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month results].
    Cornut PL, Poli M, Feldman A, El Chehab H, Swalduz B, Burillon C, Denis P.
    J Fr Ophtalmol; 2010 May; 33(5):327-33. PubMed ID: 20452098
    [Abstract] [Full Text] [Related]

  • 19. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW, Esquiabro M.
    Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
    [Abstract] [Full Text] [Related]

  • 20. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia.
    Hernández-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, Fromow-Guerra J, Amaya-Espinosa A, Solís-Vivanco A, Reyna-Castelán E, Abraham-Marín M, Martínez-Castellanos MA, Aiello LP.
    Retina; 2007 Jul; 27(6):707-12. PubMed ID: 17621179
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.